Q3 2025 Lupin Ltd Earnings Call Transcript
Key Points
- Lupin Ltd (BOM:500257) reported strong performance across key markets, achieving the highest margins in five years despite increased R&D investments.
- The US business delivered significant growth, with revenues reaching a five-year high, driven by volume growth in inline products and new product contributions.
- The company anticipates maintaining growth momentum with margins in the range of 22% to 23% for the current fiscal year.
- Lupin Ltd (BOM:500257) strengthened its diabetes portfolio with the acquisition of Eli Lilly's human insulin range for the Indian market.
- The company has a robust pipeline with over 20 respiratory products and 40 injectable products in development, aiming to file more than 30 R&Ds in the next two years.
- Muted growth in the respiratory category affected overall performance in India, despite strong growth in other key therapies.
- The emerging markets segment saw a decline of 4.7% year-on-year, impacted by currency effects.
- There are concerns about potential US tariffs on pharmaceuticals, which could impact the generic industry significantly.
- The company faces anticipated competition in key products like Albuterol and Suprep, which could affect future revenues.
- R&D expenses are expected to increase significantly in Q4, which may impact short-term profitability.
Good evening friends. I'm very pleased to welcome you to our Q3 fiscal year '25 earnings call. I have with me our Managing Director, Nilesh; our CFO Ramesh, and our head of investor relations, Ravi. We look forward to sharing with you our highlights for the quarter, as well as outlook for the year ahead.
We're very happy to report another quarter of strong performance across our key markets, both on a sequential and year-over-year basis. This has been backed by continued improvement in margins and profitability. I would like to highlight that our margins are the highest we have achieved in the last five years, despite higher investments in R&D during the period.
We feel confident of maintaining our growth momentum going ahead with margins in the range of 22% to 23% in the current fiscal year. A US business delivered strong quarter-over-quarter and year-over-year growth this this quarter with revenues at again a five year high.
This has been led by volume growth in inline products and contribution from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
